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Abstract
Background: The interleukin 32 (IL-32) is a proinflammatory cytokine produced by immune and non-immune cells.
It can be induced during bacterial and viral infections, but its production was never investigated in protozoan infections.
American Tegumentary Leishmaniasis (ATL) is caused by Leishmania protozoan leading to cutaneous, nasal or oral lesions.
The aim of this study was to evaluate the expression of IL-32 in cutaneous and mucosal lesions as well as in peripheral
blood mononuclear cells (PBMC) exposed to Leishmania (Viannia) braziliensis.
Methods: IL-32, tumour necrosis factor (TNF) and IL-10 protein expression was evaluated by immunohistochemistry in
cutaneous, mucosal lesions and compared to healthy specimens. The isoforms of IL-32α, β, δ, γ mRNA, TNF mRNA and
IL-10 mRNA were assessed by qPCR in tissue biopsies of lesions and healthy skin and mucosa. In addition, PBMC from
healthy donors were cultured with amastigotes of L. (V.) braziliensis. In lesions, the parasite subgenus was identified
by PCR-RFLP.
Results: We showed that the mRNA expression of IL-32, in particular IL-32γ was similarly up-regulated in lesions of
cutaneous (CL) or mucosal (ML) leishmaniasis patients. IL-32 protein was produced by epithelial, endothelial, mononuclear
cells and giant cells. The IL-32 protein expression was associated with TNF in ML but not in CL. IL-32 was not associated
with IL-10 in both CL and ML. Expression of TNF mRNA was higher in ML than in CL lesions, however levels of IL-10
mRNA were similar in both clinical forms. In all lesions in which the parasite was detected, L. (Viannia) subgenus was
identified. Interestingly, L. (V.) braziliensis induced only IL-32γ mRNA expression in PBMC from healthy individuals.
Conclusions: These data suggest that IL-32 plays a major role in the inflammatory process caused by L. (Viannia) sp or
that IL-32 is crucial for controlling the L. (Viannia) sp infection.
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Background
The interleukin 32 (IL-32) was initially described as natural
killer (NK) cell transcript 4 (NK4) expressed in human
activated NK and T cells [1]. After the description of sev-
eral inflammatory cytokine properties of the NK4 this pro-
tein was named IL-32 [2]. The four main isoforms of IL-32
(α, β, γ, δ), regulated by mRNA alternative splicing, are
expressed in both immune and nonimmune cells. Two
other isoforms of IL-32 (ε, ζ) that were described shortly
thereafter are highly expressed in activated T lymphocytes
[2,3]. The isoform IL-32γ presents the highest biological
activity [4]. Sequence homology between IL-32 and other
cytokines was not found, and until now a homologous
gene in mouse is not identified [2]. Most of IL-32 is
cell-associated, however depending on the cell type and
stimulus it can be released [2,5-7]. IL-32 is expressed in
inflammatory and infectious diseases as well as in healthy
tissue, mostly in epithelial cells [7-9]. Primary keratino-
cytes produces IL-32 after activation with interferon
gamma (IFNγ) and tumour necrosis factor (TNF) [7]. In
addition, TNF, IFNγ, and IL-1β induce IL-32 in intestinal
epithelial cell lines [10]. Immune cells, such as NK cells
stimulated with IL-12/IL-18, and peripheral blood mono-
nuclear cells (PBMC) cultured with mitogens also express
IL-32 [2]. Monocytes/macrophages and dendritic cells ex-
press IL-32 upon toll-like receptor (TLR) activation [5,11].
During inflammation, IL-32 can be induced by inflamma-
tory cytokines, and, in turn, IL-32 also induces other in-
flammatory mediators. It has been demonstrated that
recombinant IL-32 (α and β) induces TNF and IL-8 in hu-
man monocyte-like THP-1 cells and in murine macrophage
cell line RAW 264.7, as well as CXCL2 chemokine in mur-
ine primary macrophages. The induction of cytokines by
IL-32 involves activation of transcription factor NFκB and
p38 mitogen-activated protein kinase [2]. Moreover, IL-32
induces inflammatory mediators (TNF, IL-6, prostaglandin
E2) as well as anti-inflammatory cytokine (IL-10) in human
monocytes and monocyte-derived dendritic cells [11,12].
IL-32γ synergizes with nucleotide oligomerization domain
1 and 2 (NOD1/NOD2) ligands and with TLR2 agonist to
induce IL-1β [9,13]. Such effects has pointed out IL-32 as
an important player in the pathogenesis of inflammatory
diseases as atopic dermatitis, Crohn´s disease, rheumatoid
arthritis and rhinitis [7,10,12,14]. Especially a cross-talk be-
tween IL-32 and TNF has been described to be relevant in
the pathogenesis of these diseases [15-17]. During infection
caused by influenza A virus [18], human immunodeficiency
virus [19] or Mycobacterium avium [8] an increase of IL-32
production has been reported. Mycobacterium tuberculosis
can induce IL-32 in human monocytes in a caspase-1/IL-
18/IFNγ-dependent manner [5]. Microbicidal mechanisms
can be induced by IL-32 during these infections [18,20].
Together, these data indicate that microorganisms can in-
duce IL-32 expression in immune and nonimmune cells to
control the infection, but alternatively this cytokine might
play a role in the pathogenesis of the diseases.
American Tegumentary Leishmaniasis (ATL) is a chronic
inflammatory disease caused by Leishmania parasites. In
Brazil, the species that belong to Leishmania (Viannia) sub-
genus can induce different clinical manifestations of the
disease. The localized cutaneous leishmaniasis (CL) is most
frequent and patients can present spontaneous clinical cure.
However, mucosal leishmaniasis (ML) which affects naso-
pharyngeal and oral mucosal (with ulceration and septum
perforation) never heals spontaneously, it is difficult to
treat, and recurrence is frequent [21,22]. ML can occur
simultaneously with cutaneous lesions (mucocutaneous
leishmaniasis), however, most of the ML cases occur after
cutaneous lesions (months or years) or in the absence of
any signal of previous CL [22-25]. The detection of ML
concomitantly with cutaneous lesions is a rare event (~2.7%
of ML) [26].
In ATL, a cellular immune response (Th1 lymphocytes)
is crucial to control the infection, but it is also deleterious
to tissues leading to ulcerated lesions. The Montenegro´s
skin test (delayed hypersensitivity) reveals the strong Th1
response in ATL patients [23]. Typical Th1 cytokines,
IFNγ and TNF, are detected in lesions and these cytokines
promote macrophage activation to control the parasite
[27] but they also promote inflammation and tissue
destruction [23,28,29]. Besides inflammatory cytokines,
IL-10 is also detected in ATL lesions [28,29]. A balance
between TNF/IFNγ and IL-10 seems to be important to
control the infection and the inflammatory process
[30,31]. Because these cytokines are related to the produc-
tion and biological function of IL-32 we hypothesized that
IL-32 can be induced during Leishmania infection and to
contribute to the pathogenesis of the disease. Until now,
the presence of IL-32 was not evaluated in leishmaniasis
and in ATL IL-32 could be a crucial mediator between
epithelium and inflammatory cells. As it has been demon-
strated that IL-32γ can be spliced to IL-32β, which is less
inflammatory suggesting a balance between IL-32γ/IL-32β
to control inflammation [32], we also evaluated which iso-
forms of IL-32 are present during ATL.
Methods
Patients, controls, and tissue samples
In Annuar Auad Tropical Disease Hospital, in Goiânia,
Goiás, West Central region of Brazil, patients were diag-
nosed with cutaneous (n = 24) or mucosal (n = 10) ATL.
To be included in the study, besides a typical leishmaniasis
lesion, patients presented at least one exam indicating the
presence of parasite (Polymerase chain reaction, PCR for
Leishmania genus; histopathological analysis with immu-
nohistochemistry (IHC) for amastigotes); and also Indirect
immunofluorescence (IFI) and Montenegro´s skin test
(MST) were used at the diagnosis. All technical procedures
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were described in Oliveira et al. [33]. Patients did not
perform all tests. Before treatment, biopsy specimens were
obtained from cutaneous or nasal/oralpharyngix lesions of
ATL patients, and from healthy tissues during plastic sur-
gery (for cutaneous tissue, n = 8) or tonsil or nasal septum
surgeries (for mucosal tissues, n = 7). One fragment of
patient biopsy was fixed in 10% buffered formalin and
embedded in paraffin for histological and IHC analysis;
another one was stored in TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) for gene expression evaluation, and
the last one was stored in saline (-20°C) for molecular
characterization of parasites. For some patients the amount
of tissue fragment was not enough for all analyses. From
another set of healthy donors (n = 21, a blood sample was
collected (5 ml) for PBMC isolation. All procedures were
approved by Ethics Committee in Research of Universidade
Federal de Goiás (protocol number 165/08) and informed
consent was signed by all patients and controls (the study
included only individuals with age > 18 years).
Molecular characterization of Leishmania
First, the PCR was done to detect Leishmania genus (for
diagnosis of leishmaniasis), then the polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) was used to identify Leishmania subgenus in biopsy
fragments. Briefly, tissue lysates were obtained from frozen
biopsy fragments by adding 25 μl of TE (10 mM Tris–HCl,
1 mM EDTA, pH 8.0), and proteinase K (100 μg/ml), at
56°C, for 3 h. The DNA was extracted using the illustra™-
blood genomicPrep Mini Spin Kit (GE Healthcare UK
Limited, Buckinghamshire, UK) as recommended by the
manufacturer. The PCR was carried out using 1 μM of
each primer (to conserved region of minicircles of kDNA),
150: 5- GGG(G/T)AGGGGCGTTCT(C/G)CGAA 3- and
152: 5- (C/G)(C/G)(C/G)(A/T)CTAT(A/T) TTACACCAA
CCCC 3- [34], together with 200 μM of dNTPs, including
dUTP instead of dTTP, 0.8 U of Taq DNA polymerase
(Invitrogen), buffer (10 mM Tris–HCl pH 8.6, 50 mM KCl,
1.5 mM MgCl2) and 1 μl of DNA template, in a final vol-
ume of 10 μl. Amplification was carried out in Eppendorf
PTC-100 machine, using an initial denaturation step at 94°C
for 5 min, followed by 29 cycles at 94°C for 1 min, 59°C for
45 s, 72°C for 30 s and a final extension step of 7 min. The
PCR products were run in an 8% polyacrylamide gel in a
Mini-Protean II apparatus (Bio-Rad, Hercules, CA, USA),
followed by silver staining to visualize the bands. Positive
controls containing DNA of L. (V.) braziliensis or L. (L.)
amazonensis and a negative control without DNA were in-
cluded in each reaction set. All positive samples were sub-
jected to RFLP analysis of the amplification product [35].
The PCR products (5 μL) were used for digestion by the
addition of 1 U of Hae III (Invitrogen) for 3 h, at 37°C. The
restriction fragments were separated in a 10% polyacryl-
amide gel in the Mini-Protean II apparatus (Bio-Rad) and
silver stained. The Hae III digested the 120 bp PCR product
of L. (V.) braziliensis producing two fragments, one of 40 bp
and other of 80 bp and the enzyme did not digest L. (L.)
amazonensis amplicon.
Immunohistochemical (IHC) analysis for IL-32, IL-10, TNF
Paraffin-embedded tissues were sectioned (3 μm) and
collected in series on glass slides coated with 2% 3-
aminopropyltriethsilane (Sigma Aldrich, St. Louis, MO,
USA). The sections were deparaffinised by immersion in
xylene, and then were immersed in alcohol. For antigen
retrieval, the sections were immersed in 10 mM Tris/
1 mM EDTA buffer pH 9.0, for 30 min at 95°C, and then
incubated with 3% hydrogen peroxide (Merck SA, RJ,
Brazil) for 40 min. Sections were blocked by incubation
with Background Sniper (blocked protein, Starr Trek
Universal HRP Detection System, Biocare Medical Inc.,
Concord, CA, USA) for 15 min. The sections were im-
mediately incubated with the following primary rabbit
polyclonal antibodies (1:100 dilution): anti-IL32 (Abcam
Inc., Cambridge, MA, USA), anti-IL10 or anti-TNF
(Abcam Inc.), at 4°C, overnight, in a humidified chamber.
After washing in Tris-Buffered Saline, the sections were
treated with Link Universal Trekie (Starr Trek Universal
HRP Detection System), for 20 min, followed by washing
and treatment with TrekAvidin-HRP (Starr Trek Universal
HRP Detection System) for 20 min. Sections were then in-
cubated in Betazoid DAB Chromogen solution (Biocare
Medical Inc.) and counterstained with Mayer’s haematoxy-
lin for 30 s. Negative controls were obtained by omission
of the primary antibodies, which were substituted by 1%
phosphate-buffered saline (PBS) – Bovine Serum Albumin
(Sigma). Sections were coded and blindly analysed by two
observers. Expression of cytokines was semi quantita-
tively scored under light microscopy (400× magnifica-
tion, 10 fields per section), and classified according
scores: 0 (absence of positive cells), 1 (1% to 25% of posi-
tive cells), 2 (26% to 50% of positive cells), 3 (51% to 75%
of positive cells) and 4 (76% to 100% of positive cells),
adapted from Joosten et al. [12]. The data were repre-
sented as individuals and median values.
Cultures of PBMC and amastigote forms of Leishmania (V.)
braziliensis
Venous blood was collected in tubes containing EDTA
(BD VacutainerTM, Juiz de Fora, MG, Brazil), centrifuged
(240 g, 15 min, room temperature) and plasma was dis-
carded. The blood was diluted 1:2 in 0.01 M EDTA-PBS
pH 7.3 and layered on Ficoll (Ficoll Paque Plus, GE
Healthcare). After centrifugation (1.400 g, 15 min, room
temperature), PBMC were collected, washed twice in PBS
(600 g, 10 min, 4°C) and suspended in RPMI 1640
medium (Sigma) supplemented with 10% inactivated fetal
calf serum (FCS, Gibco), 2 mM L-glutamine (Sigma), 100
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U/ml penicillin (Sigma), and 100 μg/ml streptomycin
(Sigma). The isolate L. (V.) braziliensis MHOM/BR/2003/
IMGLb, from Leishbank (West Central region Leishmania
bank, Universidade Federal de Goiás, Brazil), characterized
as previously described [36], was used to generate amasti-
gote forms based on Ahmed et al. [37] and Lang et al.
[38] with some modifications. Briefly, promastigote forms
were cultured in 24-well plates in Grace`s insect culture
medium (Sigma) supplemented with 20% heat-inactivated
FCS (Cripion, Andradina, Brazil), 2 mM L-glutamine, 100
U/ml penicillin, and 100 μg/ml streptomycin, at 26°C
(6 days). The parasites were washed with PBS and injected
subcutaneously (5 × 106/50 μl) into one of the hind foot-
pads of IFNγ-deficient mice as previously described [33].
When lesion size was around 2 - 3 mm, animals were
sacrificed by CO2 inhalation and the footpads were asep-
tically collected, macerated in PBS, and layered on Percoll
(GE Healthcare; 44% and 100%, 2.500 g, 30 min, 10°C) to
obtain amastigotes. The PBMC (1.2 × 106/400 μl) were cul-
tured with amastigotes (3 × 105/400 μl) in duplicates, at
36°C, 5% CO2. After 24 h, PBMC were stored (RNA Store,
DNR, Jerusalem, Israel) for further IL-32 investigation.
Quantitative reverse transcription-polymerase chain
reaction (qPCR) for IL-32 isoforms, TNF and IL-10
From normal tissues, cutaneous or mucosal lesions and
PBMC, RNA extraction was done by Trizol method (Invi-
trogen). The cDNA was synthetized using SuperScript III
reverse transcriptase (Invitrogen) and Real-Time PCR re-
actions were done in an Applied Biosystems 7500 FAST
device using the IL-32 primers designed by Heinhuis et al.
[32], and detected by SYBR Green Mastermix (Applied
Biosystems, Foster City, CA, USA). Primer sequences are
presented in Table 1. Briefly, the reactions were done in a
10 μl final volume containing 5 μl of SYBR Green Master-
mix, 1 μl of each primer (5 μM), 2 μl of deionised water,
and 1 μl of cDNA. The reactions were initialized with
60°C for 20 s, followed by an step of 95°C for 10 min,
40 cycles at 95°C for 10 s, and 60°C for 1 min. At the
end of the reactions it was performed a melting curve.
GAPDH was used as the reference housekeeping gene.
The results were analysed using the 2-ΔΔCt method.
Statistical analyses
Data represent mean ± standard deviation (SD), individual
values, medians [minimal and maximal values]. Mann
Whitney and Spearman´s correlation tests were per-
formed using GraphPad Prism 5.0 Software Inc. (San
Diego, CA, USA). p < 0.05 was considered significant.
Results
Characterization of patients and parasites
As presented in Table 2, 24 patients with CL and 10 with
ML were evaluated. The mean of patient age was 38.5 ±
15.1 years for CL and 57.2 ± 17.9 years for ML patients.
Most of patients were infected in Central Brazil (67.6%,
from Goiás and Mato Grosso), but there were cases from
North and Northeast Brazilian regions. In CL, the number
of lesions was 3.5 ± 5.0, and lesion sizes were 2.7 ± 2.2 cm.
The duration of the disease was higher in ML than in CL,
varying from 15 days until 48 months in CL and from two
months until 360 months in ML group. ML patients only
presented mucosal lesions, but seven patients reported
history of previous cutaneous lesions. The majority of ML
patients showed nasal lesions (9/10) with or not oralphar-
yngix involvement (3/9). All patients presented at least
one parasitological positive test. At the diagnosis, patients
were tested for in vivo immune cellular response, varying
the MST result from 5.0 until 35 mm in CL patients,
whereas in ML patients it varied from 7 until 50 mm. In
CL group, half of patients presented two positive exams
for presence of parasites (PCR and IHC for amastigotes,
12/24, 50.0%), and most of them was positive MST and
positive PCR (14/24, 58.3%), while a less number of posi-
tive MST and positive IHC (9/24, 37.5%) was detected. In
ML group, most of patients presented positive MST and
positive PCR and/or IHC (8/10, 80.0%). The clinical and
histopathological examinations of the lesions revealed that
all were ulcerated presenting an intense inflammatory cell
infiltration composed by macrophages and lymphocytes
Table 1 Sequences of primers
Cytokine Sense Anti-sense
IL-32α 5′GCTGGAGGACGACTTCAAAGA3′ 5′GGGCTCCGTAGGACTTGTCA3′
IL-32β 5′CAGTGGAGCTGGGTCATCTCA3′ 5′GGGCCTTCAGCTTCTTCATGTCATCA3′
IL-32γ 5′AGGCCCGAATGGTAATGCT3′ 5′CCACAGTGTCCTCAGTGTCACA3′
IL-32δ 5′TCTGTCTCTCTCGGGTCCTCTCT3′ 5′TGTCTCCAGGTAGCCCTCTTTG3′
IL-10 5′GGTTCGCAAGCCTTGTCTGA 3′ 5′TCCCCCAGGGAGTTCACAT 3′
TNF 5′AAGCCTGTAGCCCATGTTGT 3′ 5′CAGATAGATGGGCTCATACC 3′
GAPDH 5′CTCAAGATTGTCAGCAATGC 3′ 5′ CAGGATGCCCTTTAGTGGGC 3′
Sequences of primers used to detect cytokine mRNA by using qPCR in leishmaniasis lesions and control tissues.
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and showed a low number of parasites. These cells could
be or not arranged in granulomas containing giant cells.
After PCR, there was amplification of the Leishmania
kDNA in 27 samples (84.4%, 27/32), being 83.3% CL
(20/24) and 87.5% ML (7/8); in two patients the PCR
was not performed). In these positive samples all para-
sites belonged to L. (Viannia) subgenus.
Expression of IL-32 protein is increased in cutaneous and
mucosal lesions of ATL patients
The expression of IL-32 was increased in cutaneous lesions
(CL: 3 [1 - 4] vs. Controls: 0.5 [0 - 2], p < 0.05, Figure 1A,
1D) as well as in mucosal lesions (ML: 3 [3 - 4] vs. Con-
trols: 1 [1 - 1], p < 0.05, Figure 1B, 1F). Similar distribution
of IL-32 was found in cutaneous or mucosal lesions. As IL-
32 can be produced by epithelial cells and mononuclear
cells, IL-32 expression was independently determined in
the epithelium and inflammatory infiltrate. The IL-32 was
found in several cells such as giant cells, endothelial
cells, mononuclear cells and keratinocytes/epithelial
cells (Figure 2A–D). The expression of IL-32 in cutaneous
and mucosal lesions was similarly detected in the epithe-
lium and in the inflammatory infiltrate (Figure 2E, 2F).
Comparing the expression of IL-32 detected in the epithe-
lium of cutaneous and mucosal lesions, no significant dif-
ferences were found. Similar results were also obtained
considering the infiltrate.
The isoform IL-32γ is up-regulated in ATL lesions
As there are different isoforms of IL-32, we investigated
the levels of mRNA of the IL-32 isoforms in healthy
tissues and in cutaneous and mucosal lesions. Among the
IL-32 isoforms investigated (α, β, γ, δ), only IL-32γ mRNA
was detected. Similar to the protein expression, signifi-
cantly higher levels of mRNA IL-32γ was detected in cuta-
neous and mucosal lesions than in healthy tissues. The
isoform IL-32γ presented 20-fold increase in cutaneous le-
sions, and 10-fold increase in mucosal lesions in relation
to control tissues. No significant differences were found
when CL was compared with ML (Figure 3).
Association of IL-32 expression with TNF and IL-10
To evaluate the association between IL-32 and other cyto-
kines in ATL, lesions and healthy tissues were submitted to
IHC for detecting TNF and IL-10. These cytokines were
variably expressed in cutaneous (CL: TNF = 3 [0 - 4] vs.
Controls: 1 [0– 1], p < 0.05, Figure 4A; IL-10 = 4 [0 - 4]
vs. Controls: 1 [0 - 1], p < 0.05, Figure 4C) as well as in
mucosal lesions (ML: TNF = 2 [ 0 - 4] vs. Controls: 0
[0 – 1], p < 0.05, Figure 4B; IL-10 = 2.5 [1 - 4] vs. Controls 1
[1 - 1], p < 0.05; Figure 4D). No differences were detected in
levels of TNF or IL-10 between CL and ML lesions. Con-
cerning the correlations between cytokine expressions, IL-
32 levels were not correlated with TNF and IL-10 levels in
CL; however, in ML a positive correlation between IL-32
and TNF was detected (r = 0.88, n = 9, p < 0.05), but not
between IL-32 and IL-10 (Table 3). A tendency of positive
correlation was found between expression of TNF and
IL-10 in CL group (r = 0.10, n = 20, Table 3).
To confirm and quantify the TNF and IL-10 expression
in tissues, a qPCR was performed. The levels of TNF
mRNA were higher in ML than in CL lesions (ML: 4,045.0
[924.0 - 40,307.0]; CL: 163.5 [29.8 - 6,888.0], Figure 5A
and 5B). However, similar to the IHC results, the levels of
IL-10 mRNA were similar in cutaneous and mucosal lesions
(CL: 328.5 [120.0 - 1,395.0]; ML: 321.0 [103.0 - 1,237.0],
Figure 5C e 5D). No associations between levels of TNF or
IL-10 mRNA with IL-32 mRNA were detected (Table 3). It
was observed a negative correlation between TNF mRNA
and protein levels in ML group (r = -0.91, p < 0.05, n = 6).
Amastigotes of L. (V.) braziliensis induces IL-32γ in
mononuclear cells from health donors
To evaluate whether the protozoan Leishmania was able
to induce IL-32, PBMC from healthy donors were incu-
bated with amastigotes of L. (V.) braziliensis for 24 h. By
using qPCR four isoforms of IL-32 (α, β, γ, δ) were in-
vestigated, but interestingly only the IL-32γ mRNA was
detected in PBMC cultures. There was ~3-fold increase
in IL-32γ in cells incubated with amastigotes in com-
parison to cultures without parasites (Figure 6).
Discussion
In the present study it was demonstrated for the first
time that IL-32 is produced during Leishmania infection.
Table 2 Characteristics of ATL patientsa
bCL cML
Male 19/24 6/10
Female 5/24 4/10
Age (years) 38.5 ± 15.1 57.2 ± 17.9
Number of lesions 3.5 ± 5.0 _
Size of Lesions (cm) 2.7 ± 2.2 _
Time of lesions (months) 7.2 ± 10.2 117.0 ± 51.0
dMST (mm) 16.1 ± 7.6 21.4 ± 13.8
Positive diagnostic test results% (positive/total tested)
ePCR 83.3 (20/24) 87.5 (7/8)
fIHC 69.6 (16/23) 66.6 (6/9)
gIFI 41.2 (7/17) 50.0 (4/8)
MST 76.2 (16/21) 100 (8/8)
aThirty four ATL patients who were assisted at Hospital de Doenças Tropicais
Anuar Auad (Goiânia - Goiás, West Central, Brazil), 24 with bCL (Cutaneous
Leishmaniasis) and 10 with cML (mucosal leishmaniasis). dMST: Montenegro
skin test; ePCR: polymerase chain reaction for Leishmania genus; fIHC:
histopathological exam with immunohistochemistry for amastigotes; gIFI:
indirect immunofluorescence; 21 patients were from West Central region of
Brazil (including 9 with ML; one was from South East); 10 from North and one
from North East.
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Patients presenting cutaneous or mucosal forms of ATL
produced similar levels of IL-32 protein and mRNA in
their lesions. In ATL lesions, the expression of IL-32 was
detected in several types of cells, including epithelial,
endothelial and mononuclear cells. The IL-32 expression
in different cell types has been previously described. In
lung of M. avium complex-infected patients IL-32 was
detected in alveolar macrophages and epithelial cells [8].
The presence of IL-32 in endothelial cells was demon-
strated indicating a role for this cytokine in inflamma-
tion [39]. In keratinocytes and other epithelial cells,
in vitro or in vivo, during infections or inflammatory dis-
eases IL-32 is produced [7,8,10,40-42]. In the present
study, IL-32 was detected in giant cells in some patient
lesions presenting tuberculoid granuloma. Recently,
Schenk et al. [43] showed that IL-32 is expressed in
granulomas in leprosy lesions with a higher frequency of
IL-32+ cells in tuberculoid than in lepromatous lesions.
However, the authors did not describe whether giant
cells were positive or not for IL-32. In leprosy, Th1 or
Th2 lymphocyte responses are associated with tubercu-
loid and lepromatous leprosy, respectively. However, in
ATL this polarization is not so clear, being detected Th1
as well as Th2 cytokines in cutaneous or mucosal lesions
with a predominance of Th1 cytokines [23,28,44]. In some
ATL lesions it is possible to detect tuberculoid granuloma
[23,45]. The presence of IL-32 in giant cells in ATL granu-
loma suggests the involvement of this cytokine in tubercu-
loid granuloma that deserves further investigation.
In this study, only IL-32γ isoform was detected in CL or
ML lesions by using qPCR. The isoforms IL-32γ and IL-
32α are mainly produced by mononuclear cells after acti-
vation [5] and they are detected in nasal mucosa tissue
during allergic rhinitis [14]. The IL-32α is also detected in
epithelial cells from colon mucosa during inflammatory
bowel disease [9,10] and IL-32β is expressed in endothelial
cells [39] and also in intestinal epithelial cell line [46]. The
isoforms IL-32γ, β and δ have been detected in fibroblast-
Figure 1 IL-32 is detected in cutaneous and mucosal lesions of ATL patients. Fragments of cutaneous lesions (CL, n = 23, A) or mucosal
lesions (ML, n = 9, B) and healthy tissues (skin, n = 8; mucosa, n = 7) were included in paraffin and sections were submitted to IHC for IL-32. After
reaction, the expression of IL-32 was determined through positive cells, analysed under light microscopy. The data represent individuals and
medians values. *p< 0.05. Panel C: photomicrography of skin control. Panel D: photomicrography of CL lesion positive for IL-32. Panel E: photomicrography
of mucosa control. Panel F: photomicrography of ML lesion positive for IL-32.
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like synoviocytes in rheumatoid arthritis [6]. Among the
IL-32 isoforms, Choi et al. [4] showed that the IL-32γ is
the most active to induce cytokines in vitro and in vivo.
The involvement of IL-32γ in inflammatory disease such
as rheumatoid arthritis has been well characterized
[12,13,17]. Based on these observations, although different
cells in CL or ML lesions can express IL-32 we suggest
that in the infiltrate the production of IL-32γ in ATL
lesions is mainly due to mononuclear cells and it can con-
tribute to chronic inflammatory process during the disease.
Besides the expression of IL-32, TNF and IL-10 were
also investigated in ATL lesions, as these cytokines can be
associated [2,7,10-12,15-17]. Similar levels of TNF and IL-
10 proteins were detected in CL and ML lesions. In
accordance with our results, Faria et al. [29] also described
similar levels of these proteins in CL and ML lesions. In
the present study, in ML and CL lesions there was an
increase in TNF gene transcription which is responsible
for TNF protein increase. Nevertheless, in ML lesions an
accumulation of TNF mRNA is more accentuated than in
CL. Several factors control the gene expression at tran-
scriptional and translational levels. The transcription rate
is initiated by cell membrane receptor signaling pathways.
At this level, we can suggest that parasite intrinsic factors
can be different in clones present in CL and in ML lesions
leading to a high transcription rate in ML [47]. However,
as protein levels were similar in CL and ML in our study,
it seems that post-transcriptional mechanisms can be
responsible for TNF mRNA accumulation in ML. In mac-
rophages, it has been demonstrated that the increase of
secreted TNF protein is largely due to transcriptional
mechanism. After cell activation, there is a fast TNF
mRNA accumulation and the translation is tightly regu-
lated [48]. These post-transcriptional mechanisms can
involve the control of mRNA stability, processing, and
translation inhibition [49]. In macrophages activated with
Figure 2 Expression of IL-32 is detected in different cells. Fragments of cutaneous or mucosal lesions were included in paraffin and sections
were submitted to IHC for IL-32. The arrows show positive cells: In panel A: mononuclear cell and giant cell; and Panel B: endothelial cells and
giant cell. In Panel C: positive keratinocytes; and Panel D: several positive mononuclear cells. The expression of IL-32 was determined, under light
microscopy, in epithelium and infiltrate of CL (E, n = 22) and ML (F, n = 9). The data represent individual and median values.
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lipopolysaccharide, increased expression of HuR, a mRNA
binding protein, enhances TNF mRNA stability and
reduces translation, causing an accumulation of mRNA
and a decrease of TNF secretion [50]. In the current study,
ML lesions showed high expression of TNF mRNA that
was negatively associated with the levels of TNF protein,
suggesting the involvement of inhibitors of TNF mRNA
translation, such as HuR. Also microRNAs are induced
during inflammation and can control the expression of
TNF at translational level. In fibroblast-like synoviocytes
from rheumatoid arthritis patients, lipopolysaccharide
induces an increase in TNF mRNA without TNF secretion
Figure 3 IL-32γ mRNA is detected in lesions of patients with cutaneous (CL) and mucosal (ML) leishmaniasis. Total mRNA was extracted
from fragments of healthy tissues (C, skin n = 8; mucosa n = 7), cutaneous lesions (CL, n = 10) or mucosal lesions (ML, n = 7), and analysed by
qPCR. Expression of isoforms α, β, γ and δ of IL-32 were analysed but only γIL-32 mRNA was detected. ND = Not detected. Results shown are
individual values and medians. *p < 005.
Figure 4 Expression of TNF and IL-10 is increased in cutaneous and mucosal lesions of ATL patients. Fragments of cutaneous (CL, A
and C), mucosal (ML, B and D), and healthy tissues (Control) were included in paraffin and sections were submitted to IHC for TNF (A and B) and
IL-10 (C and D). After reaction, the expression of cytokines was determined through quantification of positive cells, under light microscopy (400×). Data
represent individual and median values. TNF CL, n = 21; Control CL, n = 8. IL-10 CL, n = 23; Control CL, n = 8. TNF ML, n = 9; Control ML, n = 7. IL-10 ML
and Control, n = 8. p < 0.05.
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due to miR-346 control [51]. Yet, an unbalance between
microRNAs can increase or decrease TNF mRNA transla-
tion [52]. Hence, we suggest that in ML mechanisms that
control TNF mRNA translation can be more exacerbated
than in CL in attempt to decrease TNF production in-
duced by an increased gene transcription. These mecha-
nisms deserve further investigation in CL and ML lesions.
We call attention that TNF protein was semi quantified in
IHC analyses in this study, and this method cannot have
sensitivity enough to detect differences between TNF pro-
tein expression in CL and ML lesions.
In this study, IL-10 mRNA levels were similar in CL
and ML groups. In previous studies, TNF mRNA levels
were showed to be similar between CL and ML patients
whereas IL-10 mRNA was higher in ML than in CL le-
sions, when it was used reverse transcriptase PCR
[28,44]. The apparent divergence among these studies
may be related to different techniques used to measure
mRNA levels or the variability in ATL clinical character-
istics of the patients. Here, around 50% of CL patients
presented one lesion, lesions were from 0.3 until 8.0 cm
in size, and time of lesion evolution in the majority of
the patients was ≥ 3 months. In most of ML patients,
lesion evolution time was higher than 18 months (two
patients presented lesion for 2 and 4 months). It has
been described differences in TNF and IL-10 expression
between early (<2 - 3 months) and chronic (>4 months)
lesions of CL [53,54]. Correlation between size of lesion
and TNF production has been reported [33]. In our
study, we did not observe any correlation between levels
Table 3 Correlations between cytokines expressed in
cutaneous and mucosal lesions detected as protein
and mRNAa
CLb MLc
Correlations n r p n r p
IL-32 x TNF 21 -0.15 0.51 9 0.88 0.003*
IL-32 x IL-10 22 -0.03 0.90 8 0.11 0.79
TNF x IL-10 20 0.38 0.10 8 0.38 0.36
mRNA IL-32 vs. mRNA TNF 8 -0.17 0.70 7 -0.21 0.66
mRNA IL-32 vs. mRNA IL-10 8 -0.17 0.70 7 0.18 0.71
mRNA TNF vs. mRNA IL-10 10 0.28 0.43 6 0.65 0.18
aIL-32, TNF and IL-10 proteins were detected by IHC and IL-32γ, TNF and IL-10
mRNA were detected by qPCR, in biopsy fragments of lesions from bCutaneous
leishmaniasis (CL) and cMucosal leishmaniasis (ML) patients. n = number of
samples; r = Spearman´s correlation test. *p < 0.05.
Figure 5 Increase of TNF mRNA and IL-10 mRNA in lesions of ATL patients: high levels of TNF mRNA in mucosal leishmaniasis. Total mRNA
was extracted from fragments of healthy tissues (Control, skin n = 8; mucosa n = 8), cutaneous (CL, A and C, n = 10) or mucosal (ML, B and D, n = 7)
lesions, and the expressions of TNF mRNA (A, B) and IL-10 (C, D) were analysed by qPCR. Results are showed as individual and median value. *p< 0.05.
Galdino Jr et al. BMC Infectious Diseases 2014, 14:249 Page 9 of 13
http://www.biomedcentral.com/1471-2334/14/249
of cytokines (IL-32, TNF, IL-10) and these clinical find-
ings in CL or ML groups. Yet, expression of IL-32 and
TNF seems to be independent on the presence or ab-
sence of parasites in histopathological exams (data not
shown). However, protein levels of IL-10 tend to be
higher in fragments of CL lesions that do not present par-
asites than those positive for parasites (n = 17 positives vs.
n = 6 negatives, comparing levels of IL-10: p = 0.07). Thus,
we suggested that parasites induce immune responses that
control the infection and also lead to tissue injury creating
a microenvironment that maintain the chronic inflamma-
tion. Presence of parasites can be necessary to induce pro-
inflammatory cytokines, but once immune response is
established, other factors can induce IL-10 to control the
inflammation.
In the present study, analysing correlations between
cytokines, positive correlation was found between levels
of IL-32γ and TNF proteins in ML but not in CL pa-
tients. IL-32 can induce both TNF [2,12] and IL-10
[11,55]. The IL-32-induced TNF production plays a role
in inflammatory diseases such as inflammatory bowel dis-
ease and rheumatoid arthritis [10,12]. Also, TNF can in-
duce IL-32 creating an auto inflammatory loop [17]. Thus,
we suggest that IL-32γ together with TNF, and in the pres-
ence of low response to IL-10 in ML [29], can contribute
to the maintenance of the chronic inflammation in this
clinical form. In CL group it was detected a tendency of
positive correlation between TNF and IL-10, what is not
observed in ML group, suggesting that in CL the inflam-
matory mediators can be better balanced than in ML.
In an attempt to characterize the parasites, a PCR reac-
tion was used according to Passos et al. [34] and Volpini
et al. [35]. All positive biopsy fragments from CL and ML
lesions presented parasites belonging to subgenus L.
(Viannia). This is the most frequent subgenus of Leish-
mania in South America, specially represented by L. (V.)
braziliensis, causing CL or ML [56]. In West Central,
North and Northeast of Brazil, >90% of the ATL cases
have been reported to be caused by L. (V.) braziliensis
[57,58]. Only 15.6% of our tested samples were PCR nega-
tive, thus in these samples parasites causing ATL could
belong to L. (Viannia) or L. (Leishmania) subgenus. Be-
cause we detected 100% of L. (Viannia) when PCR was
positive, and the high prevalence of L. (V.) braziliensis in
Brazil, we investigated the capacity of this species to
induce IL-32 in PBMC. Amastigote forms of L. (V.)
braziliensis induced IL-32γ mRNA in healthy donor
PBMC. In some cell preparations IL-32 was not induced,
however in the presence of IFNγ it could be detected (data
not shown). The main cell population in PBMC that pro-
duces IL-32 seems to be monocytes [5], suggesting that
these cells could be the main source of IL-32γ in the
inflammatory infiltrates of ATL lesions. Only the IL-32γ
isoform was detected in PBMC as well as in ATL lesions,
suggesting that the parasites induce only this isoform or
even that L. (Viannia) sp can inhibit the expression of
another IL-32 isoforms. These results suggest that in ATL
lesions, IL-32 production can be induced by parasites and
cytokines such as IFNγ and TNF. Further experiments are
needed to understand the mechanisms of IL-32 induction
by Leishmania. The fact that IL-32 is fast induced in naive
PBMC suggests that this cytokine can be involved in
infection establishment during the first steps of parasite-
host interactions. In this study, the highest IL-32γ mRNA
Figure 6 L. (V.) braziliensis induces IL-32γ mRNA in human mononuclear cells. Mononuclear cells (3 × 106/mL) from healthy blood donors were
incubated with amastigote forms of L. (V.) braziliensis (3 × 105/well) for 24 h. The IL-32γ mRNA was analysed by qPCR. Data represent individual values
and medians (n = 21, *p < 0.05).
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expression level was detected in one lesion of 15 days of
evolution. As IL-32 was detected in all lesions evaluated,
independent on the evolution time of them, and parasite
induced this cytokine in naive PBMC, our results indicate
that IL-32 can participate in acute and chronic Leish-
mania infection.
Most of patients studied here were infected with L.
(Viannia) and L. (V.) braziliensis induced IL-32γ in PBMC
in vitro. This is the first demonstration that Leishmania
parasites are able to induce IL-32γ and that this cytokine
expression can be associated with TNF production in ML.
In ATL caused by L. (Viannia) parasites, it has been dem-
onstrated that proinflammatory Th1 cytokines (TNF, IFNγ)
are predominantly expressed in CL and ML lesions [23].
Cellular immune response is more intense in patients in-
fected with L. (V.) braziliensis than with L. (L.) amazonensis
[23]. In patients with diffuse cutaneous leishmaniasis (DCL)
caused by L. (L.) amazonensis there is a predominance of
IL-10 and Th2 cytokines [59]. In this ATL form, patients
do not present cellular immune response [23,60]. Then,
ATL can present at the centre of the clinical spectrum
localized CL, and two poles - one caused by L. (V.)
braziliensis (ML) and the other caused by L. (L.) amazonen-
sis (DCL), with intermediary form between them [59]. Our
results indicated that L. (V.) braziliensis induce strong ex-
pression of IL-32, suggesting that this cytokine can contrib-
ute to proinflammatory immune responses as it does in
chronic inflammatory diseases [10,12]. It is possible that in
L. (L.) amazonensis infections IL-32 is not highly expressed,
especially in DCL. We are investigating this possibility.
Besides the role of IL-32 in chronic inflammatory dis-
eases [10,12] it has been demonstrated that this cytokine
can be induced during infections and plays a role in im-
mune response against pathogens [5,8]. In mycobacteria-
infected cells IL-32 controls the bacteria growth [20]. Also
against viral infections IL-32 plays a role in defence mech-
anisms [18,19,40]. Based on these observations, a role of
IL-32γ in L. (Viannia) sp control must be further investi-
gated since this cytokine is present in both CL and ML
lesions and is induced by amastigotes in PBMC. This
study opens new perspectives on the understanding of
immunopathogenesis and control of leishmaniasis caused
by New World Leishmania.
Conclusions
This study shows that IL-32 is expressed in lesions of
ATL patients. This is the first report about IL-32 in
protozoan disease. IL-32 is expressed in several cells
present in the leishmaniasis lesions (epithelial and endo-
thelial cells, mononuclear cells, giant cells). The IL-32γ
is the unique isoform detected in lesions. No significant
differences between IL-32 levels of expression in CL and
ML are detected. However, in ML there is a positive cor-
relation between IL-32 and TNF which is not detected
in CL. Leishmania (V.) braziliensis is able to induce IL-
32γ in PBMC obtained from healthy donors. This study
points IL-32 as a target to be investigated in immuno-
pathogenesis and control of ATL.
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